Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
- Registration Number
- NCT01470612
- Lead Sponsor
- Pfizer
- Brief Summary
This study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP-690,550.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 944
- Subjects who completed induction studies A3921094 or A3921095 and were classified as not meeting clinical response criteria; OR
- Subjects who completed maintenance study A3921096 or who discontinued treatment early in Study A3921096 due to treatment failure.
- Subjects who had a major protocol violation in Study A3921094, A3921095 or A3921096.
- Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.
- Subjects who have had surgery for ulcerative colitis or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study period.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CP-690,550 5 mg BID CP-690,550 5 mg BID CP-690,550 10 mg BID CP-690,550 10 mg BID
- Primary Outcome Measures
Name Time Method Number of Participants With Laboratory Test Abnormalities Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group) Laboratory abnormalities: Hemoglobin, hematocrit, RBC: \<0.8\* LLN; reticulocytes (absolute \[Abs\], %): \<0.5\* LLN, \>1.5\* ULN; MCV, MCH: \<0.9\* LLN, \>1.1\* ULN; platelets:\<0.5\* LLN, \>1.75\* ULN; WBC:\<0.6\* LLN,\>1.5\* ULN; lymphocytes (Abs, %), total neutrophils (Abs,%):\<0.8\* LLN, \>1.2\* ULN; Basophils (Abs,%),eosinophils(Abs, %),monocytes(Abs, %):\>1.2\* ULN; total bilirubin,direct bilirubin,indirect bilirubin:\>1.5\* ULN; AST,ALT,gamma GT, LDH,ALP: \>3.0\* ULN; total protein,albumin: \<0.8\* LLN,\>1.2\* ULN: BUN,creatinine: \>1.3\* ULN;uric acid:\>1.2\* ULN; cholesterol,triglycerides: \>1.3\* ULN; cholesterol (HDL: \<0.8\* LLN; LDL: \>1.2\* ULN); sodium: \<0.95\* LLN, \>1.05\* ULN; potassium, chloride, calcium, bicarbonate: \<0.9\* LLN, \>1.1\* ULN; glucose: \<0.6\* LLN; creatine kinase \>2.0\* ULN; urine specific gravity: \<1.003; urine pH: \<4.5; urine (glucose,protein,blood,nitrite,leukocyte,esterase): \>=1; Urine (RBC,WBC): \>=20; urine epithelial cells:\>=6; urine (casts,granular casts,hyaline casts): \>1; urine bacteria:\>20.
Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group) Physical examinations included weight, general appearance, head, ears, eyes, nose, mouth, throat, thyroid, skin (presence of rash), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs, peripheral edema), abdominal (palpation and auscultation), perianal, musculoskeletal, extremities, neurologic (mental status, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Clinically significant changes were judged by the investigator.
Number of Participants With Electrocardiogram (ECG) Abnormalities Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group) ECG abnormalities criteria: maximum PR interval (\>=300 millisecond); maximum QRS complex (\>=200 millisecond); and maximum QT interval (\>=500 millisecond).
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.
Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs) Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group) Serious infections were treated infections that required parenteral antimicrobial therapy or hospitalization for treatment or; met other criteria that required the infection to be classified as a serious adverse event (SAE). SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state.
Number of Participants With Vital Sign Abnormalities Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group) Vital sign abnormalities included greater than or equal to (\>=) 30 millimeter of mercury \[mmHg\] increase in systolic blood pressure (BP), \>=30 mmHg decrease in systolic BP, Systolic BP (less than \[\<\] 90 mmHg), \>=20 mmHg increase in diastolic BP, \>=20 mmHg decrease in diastolic BP, diastolic BP (\<50 mmHg), pulse rate (\<40 beats per minute \[BPM\]), pulse rate (greater than \[\>\] 120 BPM).
Incidence Rates for Adjudicated Cardiovascular, Malignancy, Opportunistic Infections and Thromboembolic Safety Events Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group) Incidence rates for adjudicated cardiovascular (major adverse cardiovascular event \[MACE\]), malignancy (non-melanoma skin cancer \[NMSC\], malignancies excluding NMSC, opportunistic infections (OIs) (both herpes zoster and non herpes zoster OIs) and thromboembolic (venous thromboembolism) safety events were analyzed. This outcome measure was measured in participants with events per 100 participants-years (pt with events/100 pts-yrs).
- Secondary Outcome Measures
Name Time Method Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF) Months 2, 12, 24 and 36 Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Number of Participants With Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score >=170 at Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF) Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84 IBDQ was a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease-specific quality of life in participants with inflammatory bowel disease (IBD), including ulcerative colitis consisted of 32 items scored from 1 (worst response) to 7 (best response). For each domain, higher score indicates better quality of life (QOL). Total IBDQ score was the sum of each item score, and ranged from 32 to 224 with a higher score indicated better QOL.
Number of Participants in Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF) Months 2, 12, 24 and 36 Remission in participants was defined as a total Mayo score of \<=2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Observed Cases Months 2, 12, 24 and 36 Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Number of Participants in Remission at Months 2, 12, 24 and 36: Observed Cases Months 2, 12, 24 and 36 Remission in participants was defined as a total Mayo score of less than or equals to (\<=) 2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and physician global assessment (PGA), each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Observed Cases Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84 PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.
Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF) Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84 PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total PMS score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.
Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Observed Cases Months 2, 12, 24 and 36 Mucosal healing in participants was defined as Mayo endoscopic sub score of 0 or 1. The Mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicated higher disease severity.
Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF) Months 2, 12, 24 and 36 Mucosal healing in participants was defined as mayo endoscopic sub score of 0 or 1. The mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicating higher disease severity.
Trial Locations
- Locations (250)
Alabama Medical Group, P.C.
🇺🇸Mobile, Alabama, United States
Cedars Sinai Surgery Center
🇺🇸Los Angeles, California, United States
Atlanta Center for Gastroenterology, P.C.
🇺🇸Decatur, Georgia, United States
Gastroenterology Associates of Central Georgia, LLC
🇺🇸Macon, Georgia, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Texas Clinical Research Institute
🇺🇸Arlington, Texas, United States
Howard County GIDC
🇺🇸Columbia, Maryland, United States
Carolina Research, Carolina Digestive Diseases
🇺🇸Greenville, North Carolina, United States
Baylor College of Medicine- Baylor Medical Center
🇺🇸Houston, Texas, United States
McGovern Medical School -The University of Texas Health Science Center at Houston
🇺🇸Houston, Texas, United States
Memorial Hermann Hospital
🇺🇸Houston, Texas, United States
Royal Prince Alfred Hospital
🇦🇺Camperdown, New South Wales, Australia
Desert Sun Clinical Research, LLC
🇺🇸Tucson, Arizona, United States
Desert Sun Gastroenterology
🇺🇸Tucson, Arizona, United States
Altman Clinical and Translational Research Institute
🇺🇸La Jolla, California, United States
UCSD Medical Center
🇺🇸La Jolla, California, United States
Perlman Medical Offices - UC San Diego Health System
🇺🇸La Jolla, California, United States
Alliance Clinical Research
🇺🇸Oceanside, California, United States
Center for Endoscopy- Covenant Surgical Partners
🇺🇸Oceanside, California, United States
Connecticut Clinical Research Institute
🇺🇸Bristol, Connecticut, United States
Yale New Haven Hospital
🇺🇸New Haven, Connecticut, United States
Gastroenterology Center of Connecticut, PC
🇺🇸Hamden, Connecticut, United States
Nature Coast Clinical Research
🇺🇸Inverness, Florida, United States
North Florida Gastroenterology Research, LLC
🇺🇸Orange Park, Florida, United States
Advanced Gastroenterology Center
🇺🇸Port Orange, Florida, United States
Citrus Ambulatory Surgery Center
🇺🇸Orlando, Florida, United States
Internal Medicine Specialists
🇺🇸Orlando, Florida, United States
Advanced Medical Research Center
🇺🇸Port Orange, Florida, United States
Endoscopy Center
🇺🇸Port Orange, Florida, United States
Florida Medical Clinic, P.A.
🇺🇸Zephyrhills, Florida, United States
Port Orange Urgent Care
🇺🇸Port Orange, Florida, United States
Digestive Disease Associates, PA
🇺🇸Catonsville, Maryland, United States
Atlanta Gastroenterology Specialists, PC
🇺🇸Suwanee, Georgia, United States
Cotton O'Neil Clinical Research Center, Digestive Health
🇺🇸Topeka, Kansas, United States
East Ann Arbor Health and Geriatrics Center -UMHS
🇺🇸Ann Arbor, Michigan, United States
Gastrointestinal Diagnostic Center
🇺🇸Catonsville, Maryland, United States
MGG Group Co., Inc., Chevy Chase Clinical Research
🇺🇸Chevy Chase, Maryland, United States
Michigan Clinical Research Unit - UMHS
🇺🇸Ann Arbor, Michigan, United States
University of Michigan Health Systems
🇺🇸Ann Arbor, Michigan, United States
Clinical Research Institute of Michigan, LLC
🇺🇸Chesterfield, Michigan, United States
Medical Science Research Building 1 - UMHS
🇺🇸Ann Arbor, Michigan, United States
Surgical Centers of Michigan
🇺🇸Troy, Michigan, United States
Center for Digestive Health
🇺🇸Milwaukee, Wisconsin, United States
Huron Gastroenterology Associates - Center for Digestive Care
🇺🇸Ypsilanti, Michigan, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
AGA Clinical Research Associates, LLC
🇺🇸Egg Harbor Township, New Jersey, United States
South Jersey Gastroenterology, P.A.
🇺🇸Marlton, New Jersey, United States
NYU Langone Long Island Clinical Research Associates
🇺🇸Lake Success, New York, United States
The Gastroenterology Group of South Jersey
🇺🇸Vineland, New Jersey, United States
IBD Center - The Mount Sinai Hospital
🇺🇸New York, New York, United States
Kornbluth, Legnani, George MD, PC
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Columbia University Irving Medical Center
🇺🇸New York, New York, United States
University of Rochester
🇺🇸Rochester, New York, United States
Great Lakes Gastroenterology Research, LLC
🇺🇸Mentor, Ohio, United States
Tyler Research Institute, LLC
🇺🇸Tyler, Texas, United States
VCU Health System Endoscopy Suite
🇺🇸Richmond, Virginia, United States
VCU Health System Digestive Health Center
🇺🇸Richmond, Virginia, United States
Virginia Commonwealth University
🇺🇸Richmond, Virginia, United States
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
Nepean Hospital
🇦🇺Kingswood, New South Wales, Australia
Liverpool Hospital eastern Campus
🇦🇺Liverpool, New South Wales, Australia
Gastroenterology and Hepatology Unit
🇦🇺Clayton, Victoria, Australia
H-Hartziekenhuis Roeselare-Menen vzw
🇧🇪Roeselare, Belgium
McMaster University Medical Center
🇨🇦Hamilton, Ontario, Canada
Saskatoon City Hospital
🇨🇦Saskatoon, Saskatchewan, Canada
University Hospital Center Zagreb
ðŸ‡ðŸ‡·Zagreb, Croatia
Instituto de Coloproctologia ICO S.A.S.
🇨🇴Medellin, Antioquia, Colombia
Hepato-Gastroenterologie HK, s.r.o.
🇨🇿Hradec Kralove, Czechia
Klinicke Centrum ISCARE I.V.F., Gastroenterologie
🇨🇿Praha 7, Czechia
Nemocnice Strakonice, a.s., Interni oddeleni
🇨🇿Strakonice, Czechia
Bispebjerg Hospital
🇩🇰Copenhagen, NV, Denmark
Aalborg Hospital
🇩🇰Aalborg, Denmark
Krajska Zdravotni, A.S.,
🇨🇿Usti Nad Labem, Czechia
West Tallinn Central Hospital
🇪🇪Tallinn, Harjumaa, Estonia
CHU Amiens-Picardie - Hopital Sud
🇫🇷Amiens Cedex 01, France
CHU de Nantes - Hotel Dieu-Service d'Hepato-Gastroenterologie
🇫🇷Nantes, France
Hopital Beaujon, Gastroenterologie, MICI et Assistance Nutritive
🇫🇷Clichy, France
Hôpital Saint Louis
🇫🇷Paris, France
Hopital Haut-Leveque-CMC Magellan- Unite de Recherche Clinique
🇫🇷Pessac, France
Hopital Nord
🇫🇷St Priest En Jarez, France
Hopital Rangueil
🇫🇷Toulouse Cedex 9, France
Universitatsklinikum Schleswig-Holstein, Campus Kiel
🇩🇪Kiel, Schlewig Holstein, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Universitaesklinikum Halle, Klinik und Poliklinik fuer Innere Medizin I
🇩🇪Halle, Germany
Klinikum Lüneburg
🇩🇪Lüneburg, Germany
Gastroenterologische Gemeinschaftspraxis Minden
🇩🇪Minden, Germany
University Hospital Munich-Grosshadern
🇩🇪Munich, Germany
Universitaetsklinikum Ulm
🇩🇪Ulm, Germany
Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaza; III. Belgyogyaszat - Gasztroenterologia'.
ðŸ‡ðŸ‡ºBekescsaba, Hungary
Peterfy Sandor utcai Korhaz-Rendelointezet es Manninger Jeno Orszagos Traumatologiai Intezet
ðŸ‡ðŸ‡ºBudapest, Hungary
Debreceni Egyetem Klinikai Kozpont
ðŸ‡ðŸ‡ºDebrecen, Hungary
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza III.sz. Belgyoyaszat Gasztroenterologia
ðŸ‡ðŸ‡ºGyula, Hungary
Javorszky Odon Korhaz
ðŸ‡ðŸ‡ºVac, Hungary
The Edith Wolfson Medical Center/Gastroenterology Department
🇮🇱Holon, Israel
Rabin Medical Center, Beilinson campus
🇮🇱Petah Tikva, Israel
Aichi Medical University Hospital
🇯🇵Nagakute, Aichi, Japan
National Hospital Organization Hirosaki National Hospital
🇯🇵Hirosaki, Aomori, Japan
Toho University Sakura Medical Center
🇯🇵Sakura, Chiba, Japan
National Hospital Organization Mito Medical Center
🇯🇵Higashi-ibaraki-gun, Ibaraki, Japan
Kuniyoshi Hospital
🇯🇵Kochi-shi, Kochi, Japan
Sameshima Hospital
🇯🇵Kagoshima-shi, Kagoshima, Japan
Osaka City University Hospital
🇯🇵Osaka-City, Osaka, Japan
Osaka Medical College Hospital
🇯🇵Takatsuki-shi, Osaka, Japan
Shiga University of Medical Science Hospital
🇯🇵Otsu, Shiga, Japan
Tokyo Medical And Dental University Hospital, Faculty of Medicine
🇯🇵Bunkyo-ku, Tokyo, Japan
Jikei University Hospital
🇯🇵Minato-ku, Tokyo, Japan
Tokai University Hachioji Hospital
🇯🇵Hachioji, Tokyo, Japan
The Hospital of Hyogo College of Medicine
🇯🇵Hyogo, Japan
Keio University Hospital
🇯🇵Shinjuku-ku, Tokyo, Japan
Fukuoka University Chikushi Hospital
🇯🇵Fukuoka, Japan
Kyung Hee University Hospital
🇰🇷Seoul, Korea, Republic of
Hanyang University Guri Hospital
🇰🇷Guri-si, Gyeonggi-do, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Seoul National University Hospital,
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Digestive Diseases Center GASTRO
🇱🇻Riga, Latvia
VU University Medical Center
🇳🇱Amsterdam, Netherlands
University Medical Center Groningen (UMCG)
🇳🇱Groningen, Netherlands
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Clinical Trials Unit- Tauranga Hospital-Bay of Plenty (BOP) Clinical School
🇳🇿Tauranga, BAY OF Plenty, New Zealand
Christchurch Hospital
🇳🇿Christchurch, Canterbury, New Zealand
North Shore Hospital (Waitemata District Health Board)
🇳🇿Auckland, New Zealand
Auckland City Hospital
🇳🇿Auckland, New Zealand
Southern District Health Board
🇳🇿Dunedin, New Zealand
Waikato Hospital
🇳🇿Hamilton, New Zealand
Centrum Medyczne Szpital Sw. Rodziny Sp. z o. o.
🇵🇱Lodz, Iodzkie, Poland
P3 Research Limited
🇳🇿Wellington, New Zealand
Centrum Endoskopii Zabiegowej, Poradnia Chorob Jelitowych
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Klinika Chorob Wewnetrznych i Gastroenterologii z Pododdzialem Leczenia Nieswoistych Chorob
🇵🇱Warszawa, Mazowieckie, Poland
Gabinet Lekarski - Janusz Rudzinski
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Gabinet Endoskopii Przewodu Pokarmowego
🇵🇱Krakow, Poland
Oddzial Kliniczny Gastroenterologii Ogolnej i Onkologicznej, Uniwersytecki Szpital Kliniczny nr
🇵🇱Lodz, Poland
State budget Healthcare Institution Moscow regional scientific research clinical institute
🇷🇺Moscow, Russian Federation
State budget Institution of Healthcare Nizhniy Novgorod Regional Clinical Hospital named after N. A.
🇷🇺Nizhniy Novgorod, Russian Federation
FSBI "Scientific Research Institute of Physiology and Fundamental Medicine"
🇷🇺Novosibirsk, Russian Federation
Limited Liability Company Medical Company "Hepatolog"
🇷🇺Samara, Russian Federation
Samara Diagnostic center, X-ray Department
🇷🇺Samara, Russian Federation
State budget institution of healthcare of Yaroslavl region Regional clinical hospital
🇷🇺Yaroslavl, Russian Federation
Clinical Centre of Serbia Clinic for Gastroenterology and Hepatology
🇷🇸Belgrade, Serbia
Clinical Centre of Kragujevac Clinic for Gastroenterology and Hepatology
🇷🇸Kragujevac, Serbia
Clinical Hospital Center Zvezdara - Clinic for Gastroenterology and Hepatology
🇷🇸Belgrade, Serbia
"KM Management spol. s.r.o.Gastroenterologicke a hepatologicke centrum Nitra
🇸🇰Nitra, Slovakia
General Hospital Djordje Joanovic
🇷🇸Zrenjanin, Serbia
Medak s.r.o.
🇸🇰Bratislava, Slovakia
Clinical Centre of Vojvodina, Clinic for Gastroenterology and Hepatology
🇷🇸Novi Sad, Serbia
Poliklinika Libris, Synergy group, a.s.,
🇸🇰Nove Mesto nad Vahom, Slovakia
Chris Hani Baragwanath Academic Hospital
🇿🇦Johannesburg, Gauteng, South Africa
Panorama Medi-Clinic
🇿🇦Cape Town, Western CAPE, South Africa
Dr JP Wright
🇿🇦Cape Town, Western CAPE, South Africa
Louis Leipoldt Medical Centre
🇿🇦Cape Town, Western CAPE, South Africa
Hospital Clinic i Provincial de Barcelona
🇪🇸Barcelona, Spain
Hospital Universitario de Fuenlabrada
🇪🇸Fuenlabrada, Madrid,, Spain
Hospital Universitario de La Princesa
🇪🇸Madrid, Spain
Corporacio Sanitaria Parc Tauli
🇪🇸Barcelona, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
SI 'Institute of Gastroenterology of the NAMS of Ukraine', Dep.-nt of Stomach and Duodenum diseases
🇺🇦Dnipropetrovsk, Ukraine
Kyiv Municipal Clinical Hospital #18, Proctology Department
🇺🇦Kyiv, Ukraine
LTD "St. Paraskeva Medical Center"
🇺🇦Lviv, Ukraine
Municipal Institution "Odesa Regional Clinical Hospital", polyclinic department
🇺🇦Odesa, Ukraine
Municipal City Clinical Hospital of the Emergency Medical Care, 1-st Therapy Department of hospital,
🇺🇦Lviv, Ukraine
CI of Uzhgorod Regional Rada Uzhgorod Central Regional Hospital". Therapy Department. SHEI Uzhgorod
🇺🇦Uzhgorod, Ukraine
Bristol Royal Infirmary
🇬🇧Bristol, England, United Kingdom
Minicipal Institution City Hospital #7, Therapeutic Department,
🇺🇦Zaporizhzhia, Ukraine
The North West London Hospitals NHS Trust
🇬🇧Harrow, Middlesex, United Kingdom
UCLH NIHR Clinical Research Facility
🇬🇧London, W1t 7ha, United Kingdom
Hospital de Clinicas de Porto Alegre - HCPA
🇧🇷Porto Alegre, RIO Grande DO SUL, Brazil
Istituto Clinico Humanitas IRCCS-IBD Center
🇮🇹Rozzano, Milano, Italy
AOR Villa Sofia-Cervello
🇮🇹Palermo, PA, Italy
AOU Mater Domini - U.O. Fisiopatologia Digestiva
🇮🇹Catanzaro, Italy
Aarhus University Hospital
🇩🇰Aarhus C, Denmark
Hvidovre Hospital
🇩🇰Hvidovre, Denmark
Odense University Hospital
🇩🇰Odense C, Denmark
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Sharp Rees-Stealy Medical Group
🇺🇸San Diego, California, United States
UCSF Center for Colitis and Crohn's Disease
🇺🇸San Francisco, California, United States
Sharp Rees-Stealy Medical Group, Inc.
🇺🇸San Diego, California, United States
Clinical Applications Laboratories, Inc
🇺🇸San Diego, California, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Alpine Medical Group
🇺🇸Salt Lake City, Utah, United States
Salt Lake Regional Hospital
🇺🇸Salt Lake City, Utah, United States
Wasatch Clinical Research
🇺🇸Salt Lake City, Utah, United States
Hopital Saint Antoine - Service de Gastroenterologie
🇫🇷Paris cedex 12, France
CHU de Reims - Hopital Robert Debre
🇫🇷Reims cedex, France
London Health Sciences Centre - University Hospital
🇨🇦London, Ontario, Canada
Landeskrankenhaus Innsbruck
🇦🇹Innsbruck, Austria
The Canberra Hospital
🇦🇺Garran, Australian Capital Territory, Australia
Eastern Health, Box Hill Hospital
🇦🇺Box Hill, Victoria, Australia
GZA St Vincentius
🇧🇪Antwerpen, Belgium
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak I Belgyogyaszati-Gasztroenterologiai Osztaly
ðŸ‡ðŸ‡ºBudapest, Hungary
Endoscopy Center of Connecticut, LLC
🇺🇸Hamden, Connecticut, United States
Cedars Sinai Medical Center
🇺🇸Los Angeles, California, United States
AZ Groeninge
🇧🇪Kortrijk, Belgium
Montreal General Hospital - McGill University Health Care Centre
🇨🇦Montreal, Quebec, Canada
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
ðŸ‡ðŸ‡ºMiskolc, Hungary
Kurume University Hospital
🇯🇵Kurume, Fukuoka, Japan
Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital
🇯🇵Sapporo, Hokkaido, Japan
Showa University Hospital
🇯🇵Tokyo, Japan
NZOZ Vivamed
🇵🇱Warszawa, Poland
Cabinet Particular Policlinic Algomed SRL
🇷🇴Timisoara, Timis, Romania
Medical Research Center of Connecticut, LLC
🇺🇸Hamden, Connecticut, United States
Desert Sun Surgery Center
🇺🇸Tucson, Arizona, United States
University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre
🇨🇦Edmonton, Alberta, Canada
Pannonia Maganorvosi Centrum Kft.
ðŸ‡ðŸ‡ºBudapest, Hungary
University of Alberta - Zeidler Ledcor Centre
🇨🇦Edmonton, Alberta, Canada
Royal University Hospital
🇨🇦Saskatoon, Saskatchewan, Canada
Szent Margit Kórház, III. Belgyógyászati-Gasztroenterológiai Osztály
ðŸ‡ðŸ‡ºBudapest, Hungary
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
University of Calgary, Heritage Medical Research Clinic, TRW Building
🇨🇦Calgary, Alberta, Canada
AKH Wien, Universitaetsklinik fuer Innere Medizin III
🇦🇹Wien, Austria
UZ Leuven (University Hospital Leuven), Campus Gasthuisberg
🇧🇪Leuven, Belgium
Krankenhaus Barmherzige Brueder St. Veit/Glan
🇦🇹St. Veit an der Glan, Austria
Hopital Maisonneuve-Rosemont/Pavillon Rachel-Tourigny
🇨🇦Montreal, Quebec, Canada
Pecsi Tudomanyegyetem Klinikai Kozpont
ðŸ‡ðŸ‡ºPecs, Hungary
Rambam Health Care Campus
🇮🇱Haifa, Israel
Leiden University Medical Center
🇳🇱Leiden, Netherlands
Lexmedica
🇵🇱Wroclaw, Poland
Military Medical Academy
🇷🇸Belgrade, Central Serbia, Serbia
Gastro I., s.r.o.
🇸🇰Presov, Slovakia
Innomedica OU
🇪🇪Tallinn, Estonia
Karolina Korhaz
ðŸ‡ðŸ‡ºMosonmagyarovar, Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, I. Sz. Belgyogyaszati Klinika
ðŸ‡ðŸ‡ºSzeged, Hungary
Hiroshima University Hospital
🇯🇵Hiroshima, Japan
H-T. Centrum Medyczne - ENDOTERAPIA
🇵🇱Tychy, Slaskie, Poland
Endoskopia SP. Z O.O.
🇵🇱Sopot, Poland
Oddzial Chorob Wewnetrznych i Gastroenterologii, SP ZOZ Wojewodzki Szpital
🇵🇱Bialystok, Podlaskie, Poland
Federal State Budgetary Institution Scientific Research Institute of Physiology and Fundamental
🇷🇺Novosibirsk, Russian Federation
Kitasato University Kitasato Institute Hospital
🇯🇵Minato-ku, Tokyo, Japan
Endocare Research Centre
🇿🇦Paarl, Western CAPE, South Africa
Federal State Budgetary Institution "State Scientific Centre of Coloproctology n.a. A.N. Ryzhikh"
🇷🇺Moscow, Russian Federation
National Hospital Organization Sendai Medical Center
🇯🇵Sendai, Miyagi, Japan
Academic Medical Center (AMC)
🇳🇱Amsterdam, Netherlands
Non-State Healthcare Institution "Road Clinical Hospital at the station Samara"
🇷🇺Samara, Russian Federation
Clinical Centre of Vojvodina Emergency Internal Medicine Division
🇷🇸Novi Sad, Serbia
Hospital Universitario de Bellvitge
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Regional Municipal Institution "Chernivtsi Regional Clinical Hospital"
🇺🇦Chernivtsi, Ukraine
State Institution "L.T. Malaya Therapy Institute of NAMS of Ukraine"
🇺🇦Kharkiv, Ukraine
Spitalul Universitar de Urgenta Bucharest, Medicina Interna II Gastroenterologie
🇷🇴Bucuresti, Romania
Municipal Budget Institution of Healthcare of Novosibirsk
🇷🇺Novosibirsk, Russian Federation
Municipal Healthcare Institution Kharkiv City Clinical Hospital #2
🇺🇦Kharkiv, Ukraine
Vinnytsia Regional Clinical Hospital for War Veterans, Therapeutics Dept. No. 2
🇺🇦Vinnytsia, Ukraine
Norfolk and Norwich University Hospitals NHS Foundation Trust
🇬🇧Norwich, Norfolk, United Kingdom
Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust
🇬🇧Cambridge, England, United Kingdom
Regional Municipal Institution 'Chernivtsi Regional Clinical Hospital'
🇺🇦Chernivtsi, Ukraine
"Odesa Clinical Hospital for Railway ""Branch of ""Healthcare center of Private JSC ""Ukrainian
🇺🇦Odesa, Ukraine
Universitaetsmedizin Berlin, Charite Campus Virchow-Klinikum, Medizinische Klinik mit
🇩🇪Berlin, Germany
Wisconsin Center for Advanced Research - a division of GI Associates, LLC
🇺🇸Milwaukee, Wisconsin, United States
Hôpital Saint Louis - Service d'hepato-gastroenterologie
🇫🇷Paris, France